Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SB 211475

Known as: SB-211475 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

CarbazolesPropanolamines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
The aim of this study was to investigate the effect of SB 211475, a metabolite of carvedilol with weak alpha1-adrenoceptor… Expand
Is this relevant?
1998
1998
Effects of a hydroxylated metabolite of the beta-andrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury.
1 Reactive oxygen species have been demonstrated to play a critical role in post-ischaemic tissue injury. The present experiment… Expand
Is this relevant?
1994
1994
SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant.
The antioxidant effects of SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, were studied and compared with… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE